A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core

Zeng, Jiawei; Xu, Ling; Wang, Fengze; Duan, Xiaomin; Wang, Yue; Wu, Zheng; Yu, Dandan; Huang, Quan; Yao, Yong‐Gang; Yan, Jinghua

doi:10.1016/j.ebiom.2022.104297

Cited by 18 publications

(19 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the simultaneous and consecutive circulation of SARS-CoV-2 and seasonal influenza viruses, coupled with the looming threat posed by zoonotic influenza viruses, there is a pronounced and urgent need for the development of a combination vaccine targeting both SARS-CoV-2 and influenza viruses. Recently, various research groups have developed combination vaccines by using inactivated (33), recombinant protein (34,35), and mRNA platforms (36)(37)(38). In the present study, we have utilized our previously established mRNA vaccine platform to design and assess FLUCOV-10, a universal vaccine that targets a broader range of distinct SARS-CoV-2 and influenza viruses.…”

Section: Discussionmentioning

confidence: 99%

A 10-valent composite mRNA vaccine against both influenza and COVID-19

Wang,

Ma,

et al. 2024

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic caused by SARS-CoV-2 viruses has had a persistent and significant impact on global public health for four years. Recently, there has been a resurgence of seasonal influenza transmission worldwide. The co-circulation of SARS-CoV-2 and seasonal influenza viruses results in a dual burden on communities. Additionally, the pandemic potential of zoonotic influenza viruses, such as avian Influenza A/H5N1 and A/H7N9, remains a concern. Therefore, a combined vaccine against all these respiratory diseases is in urgent need. mRNA vaccines, with their superior efficacy, speed in development, flexibility, and cost-effectiveness, offer a promising solution for such infectious diseases and potential future pandemics. In this study, we present FLUCOV-10, a novel 10-valent mRNA vaccine created from our proven platform. This vaccine encodes hemagglutinin (HA) proteins from four seasonal influenza viruses and two avian influenza viruses with pandemic potential, as well as spike proteins from four SARS-CoV-2 variants. A two-dose immunization with the FLUCOV-10 elicited robust immune responses in mice, producing IgG antibodies, neutralizing antibodies, and antigen-specific cellular immune responses against all the vaccine-matched viruses of influenza and SARS-CoV-2. Remarkably, the FLUCOV-10 immunization provided complete protection in mouse models against both homologous and heterologous strains of influenza and SARS-CoV-2. These results highlight the potential of FLUCOV-10 as an effective vaccine candidate for the prevention of influenza and COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

A 10-valent composite mRNA vaccine against both influenza and COVID-19

Wang,

Ma,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…HAI of immunized mouse sera was performed as previously described 14 . First, serum samples were treated with receptor‐destroying enzymes (Denka Seiken) overnight at 37°C and heat‐inactivated at 56°C for 30 min.…”

Section: Methodsmentioning

confidence: 99%

“…9 Also, COVID-19 vaccination has effectively reduced severe cases and mortality rate. 10,11 Many dual-vaccination strategies are currently in the developmental stage, such as the virion-based vaccine, 12,13 receptor-binding domain (RBD)-based vaccine, 14 RBD-conjugated inactivated IAV, 15 mRNA vaccine, 8 chimpanzee adenovirus 68 (AdC68)-based vaccine, 16 and recombinant VSV-based bivalent vaccine. 17…”

Section: Introductionmentioning

confidence: 99%

A subunit‐based influenza/SARS‐CoV‐2 Omicron combined vaccine induced potent protective immunity in BALB/c mice

Zhang,

Ye,

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Infection with influenza A virus (IAV) and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) poses a significant risk to human life, health, and the global economy. Vaccination is one of the most effective strategies in the fight against infectious viruses. In this study, we, for the first time, have evaluated the immunogenicity and protective effect of an influenza/SARS‐CoV‐2 Omicron subunit combined vaccine adjuvanted with MF59 and administered to BALB/c mice. Results showed that the combined vaccine induced high levels of IgG, IgG1, and IgG2a antibodies, as well as influenza A H1N1/California/2009 virus‐specific hemagglutination‐inhibiting antibodies in BALB/c mice. Moreover, this subunit combined vaccine induced high titers of neutralization antibodies against SARS‐CoV‐2 Omicron sublineage BA.5 pseudovirus and effectively reduced the viral load of authentic SARS‐CoV‐2 Omicron sublineage BA.5.2 in the cell culture supernatants. These results suggested that this subunit combined vaccine achieved protective effect against both H1N1 A/California/07/2009 strain and SARS‐CoV‐2 Omicron BA.5.2 variant. It is therefore expected that this study will establish the scientific foundation for the next‐step development of combined vaccines against other strains or variants of IAV and SARS‐CoV‐2.

show abstract

“…ICS assay was performed to detect antigen-specific CD4+ T cell and CD8+ T cell immune responses [ 14 ]. The splenocytes from each immunized C57BL/6 mice were cultured with RPMI 1640 containing 10% FBS in 96-well flat-bottom plates (2 × 10 6 cells/well).…”

Section: Methodsmentioning

confidence: 99%

Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge

Zeng

Jiang

et al. 2023

Emerging Microbes & Infections

Self Cite

View full text Add to dashboard Cite

Current unprecedented mpox outbreaks in non-endemic regions represent a global public health concern. Although two live-attenuated vaccinia virus (VACV)-based vaccines have been urgently approved for people at high risk for mpox, a safer and more effective vaccine that can be available for the general public is desperately needed. By utilizing a simplified manufacturing strategy of mixing DNA plasmids before transcription, we developed two multi-antigen mRNA vaccine candidates, which encode four (M1, A29, B6, A35, termed as Rmix4) or six (M1, H3, A29, E8, B6, A35, termed as Rmix6) mpox virus antigens. We demonstrated that those mpox multi-antigen mRNA vaccine candidates elicited similar potent cross-neutralizing immune responses against VACV, and compared to Rmix4, Rmix6 elicited significantly stronger cellular immune responses. Moreover, immunization with both vaccine candidates protected mice from the lethal VACV challenge. Investigation of B-cell receptor (BCR) repertoire elicited by mpox individual antigen demonstrated that the M1 antigen efficiently induced neutralizing antibody responses, and all neutralizing antibodies among the top 20 frequent antibodies appeared to target the same conformational epitope as 7D11, revealing potential vulnerability to viral immune evasion. Our findings suggest that Rmix4 and Rmix6 from a simplified manufacturing process are promising candidates to combat mpox.

show abstract

A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core

Cited by 18 publications

References 68 publications

A 10-valent composite mRNA vaccine against both influenza and COVID-19

A 10-valent composite mRNA vaccine against both influenza and COVID-19

A subunit‐based influenza/SARS‐CoV‐2 Omicron combined vaccine induced potent protective immunity in BALB/c mice

Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge

Contact Info

Product

Resources

About